Interação entre Ciclosporina e Micofenolato
Ciclosporina e Micofenolato: ambas as bulas profissionais sinalizam esta combinação com a linguagem mais forte, como uma contraindicação, uma advertência em caixa preta ou uma instrução para evitá-la.
Não combine sem a orientação de um prescritor. A linguagem da bula abaixo é a mais forte que a FDA usa.
O que dizem as bulas da FDA
Da bula de Ciclosporina (Neoral) · em vigor desde 2026-08-10
In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents.
For Psoriasis Patients (see also BOXED WARNING above) Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Neoral.
Psoriasis Psoriasis patients who are treated with Neoral should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy.
Concomitant administration of cyclosporine and mycophenolate mofetil or mycophenolate sodium in transplant patients may decrease the mean exposure of MPA by 20% - 50% when compared with other immunosuppressants, which could reduce efficacy of mycophenolate mofetil or mycophenolate sodium.
Monitor patients for alterations in efficacy of mycophenolate mofetil or mycophenolate sodium, when they are coadministered with cyclosporine.
Da bula de Micofenolato (Mycophenolate Mofetil) · em vigor desde 2026-08-06
Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate…
Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )].
Post-transplant lymphoproliferative disorder (PTLD) developed in 0.4% to 1% of patients receiving mycophenolate mofetil (2 g or 3 g) with other immunosuppressive agents in controlled clinical trials of kidney, heart and liver transplant patients [see Adverse Reactions ( 6.1 )] .
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressive agents.
Toma mais do que estes dois? As interações se acumulam. Verifique sua lista inteira de uma vez; ela fica no seu navegador.
Abrir no verificadorNão é aconselhamento médico. Interaction Checker cita o texto das bulas da FDA e fichas informativas do NIH. A importância de uma interação para você depende das doses, dos horários, da função renal e hepática e de outras condições de saúde. Confirme com um farmacêutico ou com o prescritor.